Grigull L, Beilken A, Schrappe M, Das A, Luecke T, Sander A, Stanulla M, Rehe K, Sauer M, Schmid H, Welte K, Lukacs Z, Gal A, Sykora K W
Pediatric Hematology and Oncology, Children's Hospital, Hannover Medical University, Hannover, Germany.
Bone Marrow Transplant. 2005 Feb;35(3):265-9. doi: 10.1038/sj.bmt.1704786.
Hurler syndrome (MPS1H) is a progressive inborn error of mucopolysaccharide metabolism leading to premature death. Allogeneic hematopoietic cell transplantation (HCT) can achieve stabilization and improve long-term survival. However, large studies have shown that preparative regimen-related toxicity (RRT) and graft failure rates have been relatively high. We transplanted five Hurler children with a fludarabine-based conditioning regimen, consisting of fludarabine/busulphan/ATG for matched family donor (MFD), with the addition of melphalan for mismatched family donor and matched unrelated donor (MUD) transplantations. Median age at HCT was 27 months (range 10-36). The source of stem cells was bone marrow in one MFD and CD34-selected PBSC in four patients. Median CD34+ cell dose was 25 x 10(6)/kg (range 11.5-54). No RRT > grade II was observed. All patients are surviving at a median of 32 months (range 14-41) and show sustained donor engraftment with 3/5 having full donor chimerism, and 2/5 mixed chimerism (> 85%). We conclude that this regimen is feasible and has low toxicity in Hurler children. In combination with high doses of CD34+ selected cells (> 10 x 10(6)/kg) and donor lymphocyte infusions, stable engraftment could be achieved in unrelated and mismatched related transplantations.
黏多糖贮积症Ⅰ型(胡尔勒综合征,MPS1H)是一种进行性先天性黏多糖代谢障碍疾病,可导致过早死亡。异基因造血细胞移植(HCT)可实现病情稳定并提高长期生存率。然而,大型研究表明,预处理方案相关毒性(RRT)和移植失败率一直相对较高。我们采用了一种以氟达拉滨为基础的预处理方案对5名患有胡尔勒综合征的儿童进行移植,对于匹配的家族供体(MFD),该方案由氟达拉滨/白消安/抗胸腺细胞球蛋白组成,对于不匹配的家族供体和匹配的无关供体(MUD)移植,则添加美法仑。HCT时的中位年龄为27个月(范围10 - 36个月)。1例MFD患者的干细胞来源为骨髓,4例患者为CD34选择的外周血干细胞。CD34 +细胞中位剂量为25×10⁶/kg(范围11.5 - 54)。未观察到RRT > Ⅱ级的情况。所有患者均存活,中位生存期为32个月(范围14 - 41个月),均显示供体持续植入,5例中有3例为完全供体嵌合,2例为混合嵌合(> 85%)。我们得出结论,该方案对患有胡尔勒综合征的儿童是可行的且毒性较低。结合高剂量的CD34 +选择细胞(> 10×10⁶/kg)和供体淋巴细胞输注,在无关和不匹配相关移植中可实现稳定植入。